ACLARIS THERAPEUTICS INC
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- $84.9M
- Website
- http://www.aclaristx.com
Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06585202
- Locations
- 🇺🇸
Aclaris Investigational Site, San Antonio, Texas, United States
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05511519
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
🇺🇸Aclaris Clinical Operations, Charlotte, North Carolina, United States
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05432596
- Locations
- 🇺🇸
Aclaris Investigational Site, Richmond, Virginia, United States
ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT05279417
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05216224
- Locations
- 🇺🇸
Aclaris Investigational Site, Sugar Land, Texas, United States
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04598269
- Locations
- 🇺🇸
Aclaris Investigational Site, Newport News, Virginia, United States
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04524858
- Locations
- 🇺🇸
Aclaris Investigational Site, San Francisco, California, United States
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04247815
- Locations
- 🇺🇸
Aclaris Investigational Site, Mesquite, Texas, United States
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03812510
- Locations
- 🇺🇸
Aclaris Investigational Sites, Omaha, Nebraska, United States
🇺🇸Aclaris Invesgational Site, Broomall, Pennsylvania, United States
🇺🇸Aclaris Investigational Site, Spokane, Washington, United States
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03759340
- Locations
- 🇺🇸
Aclaris Investigator SIte, Detroit, Michigan, United States
🇺🇸Aclaris Investigational Site, Austin, Texas, United States
🇺🇸Aclaris Investigator Site, Lynchburg, Virginia, United States